Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
PLoS One ; 15(12): e0243647, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33301505

RESUMO

Mannanase 19287 enzyme is an engineered ß-mannanase that can be added to diets for animals raised for human consumption to hydrolyze ß-mannans. Established toxicological analyses were conducted with the enzyme preparation to ensure the safety of this product for the intended use. The mannanase 19287 preparation was produced with Thermothelomyces thermophilus strain DSM 33149. In vitro toxicity studies presented here used dosages of the mannanase 19287 test articles up to 5000 µg/plate. For in vivo toxicity studies in Wistar rats, test articles were administered at 5.1 mg/L for inhalation toxicity and up to 15,000 mg/kg rat feed for oral toxicity, based on the Total Organic Solids (TOS) content in each test article. No treatment related adverse effects were reported in any study. The No Observed Adverse Effect Levels in the high dose group of the subchronic oral toxicity study were calculated as 1117-1298 mg TOS/kg bw/day in rats. Comparing these values to an Estimated Daily Intake for poultry demonstrated safety factors larger than 5000. Our results confirm that T. thermophilus fulfills the recognized safety criteria for the manufacture of food enzyme preparations and represent the first peer-reviewed safety evaluation of an enzyme preparation by T. thermophilus. The results of the toxicity studies presented herein attest to the safety of the mannanase 19287 enzyme for its intended use.


Assuntos
Ração Animal/efeitos adversos , Proteínas de Bactérias/efeitos adversos , Sordariales/genética , beta-Manosidase/efeitos adversos , Ração Animal/análise , Animais , Proteínas de Bactérias/genética , Feminino , Humanos , Microbiologia Industrial , Masculino , Nível de Efeito Adverso não Observado , Engenharia de Proteínas , Ratos Wistar , beta-Manosidase/genética
2.
PLoS One ; 11(10): e0164622, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27736961

RESUMO

Biofilm is an important virulence factor in Pseudomonas aeruginosa and has a substantial role in antibiotic resistance and chronic burn wound infections. New therapeutic agents against P. aeruginosa, degrading biofilms in burn wounds and improving the efficacy of current antimicrobial agents, are required. In this study, the effects of α-mannosidase, ß-mannosidase and trypsin enzymes on the degradation of P. aeruginosa biofilms and on the reduction of ceftazidime minimum biofilm eliminating concentrations (MBEC) were evaluated. All tested enzymes, destroyed the biofilms and reduced the ceftazidime MBECs. However, only trypsin had no cytotoxic effect on A-431 human epidermoid carcinoma cell lines. In conclusion, since trypsin had better features than mannosidase enzymes, it can be a promising agent in combatting P. aeruginosa burn wound infections.


Assuntos
Queimaduras/complicações , Manosidases/farmacologia , Infecções por Pseudomonas/microbiologia , Pseudomonas aeruginosa/efeitos dos fármacos , Tripsina/farmacologia , Infecção dos Ferimentos/microbiologia , Biofilmes/efeitos dos fármacos , Ceftazidima/farmacologia , Linhagem Celular , Humanos , Manosidases/efeitos adversos , Testes de Sensibilidade Microbiana , Infecções por Pseudomonas/tratamento farmacológico , Pseudomonas aeruginosa/isolamento & purificação , Tripsina/uso terapêutico , Infecção dos Ferimentos/tratamento farmacológico , alfa-Manosidase/efeitos adversos , alfa-Manosidase/farmacologia , beta-Manosidase/efeitos adversos , beta-Manosidase/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...